RheumaGen is engineering a cure for rheumatoid arthritis (RA), multiple sclerosis (MS), and other major autoimmune diseases using HLA gene editing. Our approach builds upon clinically proven methods to collect and edit hematopoietic stem cells which allow us to safely transform harmful HLA alleles into healthy ones. RheumaGen has received excellent initial FDA feedback and is preparing an IND submission to begin Phase I with refractory RA patients in Q4 2025.
Website: www.rheumagen.com